Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis

Fig. 4

Relative risks (RRs) of discontinuation due to TRAEs in NSCLC.

(A) Forest plot of RR of treatment discontinuation due to TRAEs. (B) Direct and overall comparisons of discontinuation due to TRAEs. Each cell contains pooled RR with 95% CI. An RR greater than 1 means that upper-row treatment has a greater risk of treatment discontinuation. The overall comparison outcomes, which combine direct and indirect comparison results from the network meta-analysis are displayed in the left lower half, while results from pairwise meta-analysis are shown in the right upper half, if available. Significant results are in bold. Chemo-dual-IO indicates dual-immunotherapy combined with chemotherapy; Chemo-IO, mono-immunotherapy combined with chemotherapy; Chemo-only, chemotherapy alone; CI, confidence interval; dual-IO, dual-immunotherapy; mono-IO, mono-immunotherapy; NA, not available; NSCLC, non-small cell lung cancer; RR, relative risk; TRAE, treatment-related adverse event

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us